An Exploratory Clinical Study Evaluating Allogeneic iPSC-derived Pancreatic Islet Cells (CRG-002) for the Treatment of Diabetic Patients With Hypoglycemia Unawareness or Severe Hypoglycemic Events

NCT07503028 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

ENROLLING_BY_INVITATION

Status

10

Enrollment

INDUSTRY

Sponsor class

Conditions

T1DM - Type 1 Diabetes Mellitus
Pancreatogenic Diabetes Mellitus

Interventions

DRUG: CRG002

Sponsor

Celregen Therapeutics